Related Experiment Video
Updated: Jul 6, 2026
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Tuberculosis treatment outcomes and their determinants among patients attending Hargeisa TB Hospital: a five-year
Ahmed Ibrahim Farah1,2,3, Ahmed Ahmed4, Jama Mohamed5
1College of Health and Medical Sciences, University of Hargeisa, Hargeisa, Somaliland.
Introduction:
tuberculosis (TB) is one of the major public health threats and the leading infectious disease worldwide. Assessing TB treatment outcomes and associated risk factors is crucial for effective treatment and control. This study aimed to investigate TB treatment outcomes and their related factors in Hargeisa, Somaliland.
Methods:
a five-year, hospital-based retrospective study was conducted at Hargeisa TB Hospital, Somaliland, from January 1st, 2019, to December 31st, 2023. A total of 6127 registered patients, including only 6069 TB patients with complete information, were included in the study. Demographic, clinical, and treatment characteristics of the study participants were gathered from the TB register using a pretested structured data abstraction template. Data were entered and analyzed using R 4.2.2 software, with a p-value < 0.05 considered statistically significant.
Results:
the overall successful treatment outcome was 81.2%. Among all TB patients, 31.9% of males and 21.8% of females completed their treatment. Younger patients (<20 years) showed a higher likelihood of success, as indicated by adjusted odds ratio (AOR= 2.89, 95% CI: 2.35-3.56), followed by patients aged 20-40 (AOR= 2.43, 95% CI: 1.98-2.98) and 40-60 (AOR= 1.54, 95% CI: 1.23-1.93). Patients with extrapulmonary tuberculosis (EPTB) had lower odds of successful treatment compared to those with pulmonary TB (AOR= 0.75, 95% CI: 0.66-0.86). Human Immunodeficiency virus (HIV)- negative patients were more likely to achieve a successful outcome (AOR= 2.75, 95% CI: 1.82-4.10), and the likelihood of success increased progressively over the years, with 2023 showing the highest odds (AOR= 2.66, 95% CI: 2.14-3.30).
Conclusion:
the overall treatment outcome was below the World Health Organization (WHO) target (90%). Therefore, the study recommends improvements in TB treatment strategies, focusing on at-risk groups for less treatment success, including older individuals and HIV-coinfected TB patients.
Related Concept Videos
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:31Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:23Tuberculosis